A monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca reduced the risk of symptoms in a study of immunocompromised and chronically ill adults later exposed to the virus by 77%, the company announced today.
In a new article published in JNCI Cancer Spectrum, Moffitt Cancer Center researchers describe a prediction model they have created that includes information calculated from computed tomography images that can identify non-small cell lung cancer patients who are not likely to respond to immunotherapy.
The early COVID-19 vaccination campaign in the U.S. prevented nearly 140,000 deaths and 3 million cases of COVID-19 by the second week of May, according to a new study.
Expert Q&A: Do breakthrough cases mean we will soon need COVID boosters? The extremely contagious Delta variant continues to spread, prompting mask mandates, proof of vaccination, and other measures. Media invited to ask the experts about these and related topics.
T cells play an important role in the human immune system.
A new preclinical study led by researchers at the UCLA Jonsson Comprehensive Cancer Center suggests that treating people who have aggressive cancers, including melanoma, pancreatic and colorectal cancers, with immune checkpoint inhibitors, quickly followed with mutation-targeted therapy, can help overcome treatment resistance and help people live longer.
Regardless of COVID vaccination and past infection status, the real measurement of immunity for COVID is the quantity and quality of antibodies each person has. Researchers at Sinai Hospital in Baltimore are offering a glimpse at how widespread, rapid antibody testing may be conducted in the near future. This new testing methodology is 99.5% effective, is easy to use, works and looks like a home pregnancy test and yields results in 15-20 minutes allowing for mass testing, particularly amongst children, older adults, and other populations resistant to blood draws. The researchers say the testing may be the easiest, fastest way to determine if someone needs a booster shot.
Penn researchers have discovered that TSLP stimulates the immune system to release lipids through the skin’s oil-producing sebaceous glands in mice.
Researchers at Washington University School of Medicine in St. Louis have found that the delta variant of the virus that causes COVID-19 is largely unable to evade antibodies elicited by vaccination. The findings help explain why vaccinated people have been at low risk of getting seriously ill with COVID-19 despite a surge in cases caused by the delta variant.
Messenger-RNA (mRNA) vaccines against the coronavirus that causes COVID-19 provoke a swift and strong response by the immune system’s T cells—the heavy armor of the immune system—according to a study from researchers in the Perelman School of Medicine at the University of Pennsylvania.
The FDA and CDC have just approved and recommended an additional dose of mRNA COVID-19 vaccines for moderately and severely immunocompromised people. Who should get it?
Patients receiving in-hospital dialysis treatment for kidney disease produce a larger neutralising antibody response when given the Pfizer-BioNTech COVID-19 vaccine, compared to the Oxford-AstraZeneca vaccine, according to laboratory findings published today (Thursday) as a Correspondence in The Lancet.
Researchers in Moffitt Cancer Center’s Lung Cancer Center of Excellence believe a combination of checkpoint inhibitors with adoptive cell therapy could be the answer for non-small cell lung cancer patients. Results of their investigator-initiated phase 1 clinical trial evaluating the checkpoint inhibitor nivolumab in combination with tumor infiltrating lymphocyte (TIL) therapy was published today in Nature Medicine.
A two-arm molecule can effectively deplete cancer-protecting cells inside tumors, allowing the immune system to fight off tumors without becoming overactive. The finding, published online in Science Translational Medicine, could leaA two-arm molecule can effectively deplete cancer-protecting cells inside tumors, allowing the immune system to fight off tumors without becoming overactive. The finding, published online in Science Translational Medicine, could lead to new types of cancer immunotherapies.d to new types of cancer immunotherapies.
Mount Sinai researchers have found an important clue to a rare but serious aftereffect of COVID-19 in children, known as multisystem inflammatory syndrome in children or MIS-C.
妙佑医疗国际(Mayo Clinic) 的研究人员发现，与COVID-19（2019 冠状病毒病）相关的急性肾损伤类似于败血症引起的肾损伤，而且感染引发的免疫反应起着关键作用。
Os pesquisadores da Mayo Clinic descobriram que a lesão renal aguda associada com a COVID-19 é muito similar à lesão renal causada por sepse e que a resposta imunológica ativada pela doença exerce um papel central.
اكتشف باحثو مايو كلينك أن إصابة الكُلى الحادة المرتبطة بفيروس كورونا المستجد كوفيد-19 تماثل إصابة الكُلى الناتجة عن الإنتان، وتلعب الاستجابة المناعية الناجمة عن العدوى دورًا محوريًا فيها.
The levels of IgG antibodies against SARS-CoV-2 Spike protein remain stable, or even increase, seven months after infection, according to a follow-up study in a cohort of healthcare workers coordinated by the Barcelona Institute for Global Health (ISGlobal), an institution supported by “la Caixa” Foundation, in collaboration with the Hospital Clinic of Barcelona.
UC San Diego researchers report that solid organ transplant recipients who were vaccinated experienced an almost 80 percent reduction in the incidence of symptomatic COVID-19 compared to unvaccinated counterparts during the same time.
In an article in the New England Journal of Medicine, scientists from Fred Hutchinson Cancer Research Center, Johns Hopkins Bloomberg School of Medicine, the U.S. Military HIV Research Program and the Institute for Global Health and Infectious Diseases at the University of North Carolina urged increased attention to persistent COVID-19 infections in immunocompromised people.
A KAIST immunology research team found that a specific subtype of macrophages that originated from blood monocytes plays a key role in the hyper-inflammatory response in SARS-CoV-2 infected lungs, by performing single-cell RNA sequencing of bronchoalveolar lavage fluid cells.
The US Food and Drug Administration approved the drug anifrolumab (Saphnelo) on August 2, 2021 for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy. Much of the groundwork for the development of this drug was done in laboratories at Hospital for Special Surgery (HSS) in the early 2000s.
Scientists at Children’s Hospital of Philadelphia (CHOP) have identified two proteins that could be used for a potential vaccine against nontypeable Haemophilus influenzae (NTHi). Working in a mouse model, the investigators found that administering two bacterial adhesive proteins that play a key role in helping the bacteria to latch on to respiratory cells and initiate respiratory tract infection stimulated protective immunity against diverse NTHi strains, highlighting the vaccine potential.
Johns Hopkins Medicine researchers, in collaboration with national and international researchers, have identified a genetic mutation in a small number of children with a rare type of inflammatory bowel disease. The discovery of the mutation, which weakens the activity of a protein linked to how the immune system fights viruses in the gut, may help researchers pinpoint the cause of more common bowel diseases, investigators say.
Dr. K. Bao Vang-Dings, a nanotechnology researcher at the University of Arkansas at Little Rock, has been named one of nine 2021-22 Public Policy Fellows by the American Association of Immunologists. Additionally, the Arkansas IDeA Network of Biomedical Research Excellence (INBRE) has awarded her a 2021 Summer Research Grant to support Vang-Dings’ cancer vaccine research.
Göttingen researchers have developed mini-antibodies that efficiently block the coronavirus SARS-CoV-2 and its dangerous new variants.
DALLAS – July 28, 2021 – The body’s ability to prevent food poisoning by producing a natural antimicrobial compound increases during the day, when exposure to noxious bacteria is most likely, a new study by UT Southwestern scientists suggests. The findings, published online in Cell, could eventually lead to timed therapies and vaccination regimens designed to maximize this immune response.
Gut reaction: Cornell researchers “humanized” mice with microbiota from three global populations and found that microbial differences alone can impact immune responses.
One in four cancer patients lack sufficient immunity against measles and mumps, study finds
New research conducted in monkeys reveals that T cells are not critical for the recovery of primates from acute COVID-19 infections.
The body's first encounter with SARS-CoV-2, the virus behind COVID-19, happens in the nose and throat, or nasopharynx.
Researchers studied cells collected by nasal swabs at the moment of diagnosis for both mild and severe COVID-19 patients
Researchers have discovered a limitation of the immune system in battles against cancers or viruses: T cells remain programmed to stay exhausted even weeks after exposure to a virus ended. Scientists need to take this "T cell exhaustion” into account when devising immune-based therapies.
Panelists will discuss the threat posed by new COVID variants and continued vaccine hesitancy.
Advanced technologies have been used to solve a long-standing mystery about why some people develop serious illness when they are infected with the malaria parasite, while others carry the infection asymptomatically.
As the SARS-CoV-2 virus that causes COVID-19 continues to evolve, immunologists and infectious diseases experts are eager to know whether new variants are resistant to the human antibodies that recognized initial versions of the virus.
Researchers at Cornell have developed a way to analyze how individual immune cells react to the bacteria that cause tuberculosis. It could pave the way for new vaccine strategies and provide insights into fighting other infectious diseases.
UT Southwestern researchers report the first structural confirmation that endogenous – or self-made – molecules can set off innate immunity in mammals via a pair of immune cell proteins called the TLR4−MD-2 receptor complex. The work has wide-ranging implications for finding ways to treat and possibly prevent autoimmune diseases such as multiple sclerosis and antiphospholipid syndrome.
Cancer Research Institute announced grants and fellowships of $28.5 million to scientists advancing immunology and cancer immunotherapy research
Cancer Research Institute announces first recipients of new fellowship program designed to promote racial diversity and inclusion in immunology and tumor immunology
UT Southwestern researchers have identified an immune protein tied to the rare neurodegenerative condition known as Niemann-Pick disease type C. The finding, made in mouse models and published online in Nature, could offer a powerful new therapeutic target for Niemann-Pick disease type C, a condition that was identified more than a century ago but still lacks effective treatments.
SARS-CoV-2 still poses major challenges to mankind. The frequent emergence of mutant forms makes the threat posed by the virus difficult to predict.
The parasites that cause severe malaria are well-known for the sinister ways they infect humans, but new research may lead to drugs that could block one of their most reliable weapons: interference with the immune response.
Regulatory T cells (Tregs) help control inflammation and autoimmunity in the body. Unfortunately, it has proven difficult to find the right molecular ingredients to induce stable iTregs. A new study reports that Vitamin C and TET proteins can work together to give Tregs their life-saving power.
Research led by the University of Southampton into the uptake of the COVID-19 vaccine in Ghana, West Africa has concluded that vaccine hesitancy has seen a small, but significant increase over the last three months.
A UC San Francisco study has found that the antibiotic azithromycin was no more effective than a placebo in preventing symptoms of COVID-19 among non-hospitalized patients, and may increase their chance of hospitalization, despite widespread prescription of the antibiotic for the disease.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right